Application No.: 09/716,778 **Docket No.: 29473/11899**

REMARKS

This paper is filed in order to elect a species and to amend the claims in response to telephonic interviews with the examiner.

Examiner Audet requested that the applicants elect a species from one of the sequences in claim 10. In response, the applicants elect the species set out in subsection (iii) of claim 10, *i.e.*, S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-GNNDESNISFKEK (SEQ ID NO:7).

The claims have been rewritten as method of treating wound claims, and the title of the application has been amended consistent with the subject matter of the amended claims.

New claim 13-16 are found in original claim 1. New claims 17-19 are found in original coaim 6.

June 27, 2003

Respectfully submitted,

By _____

James P. Zeller
Registration No. 28,491
MARSHALL, GERSTEIN & BORUN
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6357
(312) 474-6300
Attorneys for Applicant

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

1. (Currently Amended) [Application of] A method of treating a wound in an animal or human comprising administering to said animal or human a pharmaceutical composition comprising a lipopeptide or lipoprotein with the following general structure:



[in which] wherein

R^1 and R^2[, which can be the same or different,] stand for C_{7-25}-alkyl. C_{7-25}-alkenyl or C_{7-25}-alkinyl,

X is S, O, or CH_2,

Z^1 and Z^2[, which can be the same or different,] stand for H or methyl,

W stands for CO or $S(O)_n$ (where n = 1 or 2) and

Y stands for a physiologically compatible amino acid sequence consisting of 1 to 25 amino acid residues and the asymmetric carbon atom marked with * has the absolute configuration S when X = S (sulfur)[, for the preparation of a pharmaceutical preparation for treatment of wounds in animals or humans].

2. (Currently Amended) [Application according to] The method of Claim 1, [characterized by the fact that] wherein Y [stands for a physiologically compatible] comprises an amino acid sequence consisting of 1 to 25 amino acids.

3. (Currently Amended) [Application according to] The method of Claim 1, [characterized by the fact that] wherein Y [stands for] comprises an amino acid sequence which is selected from the [following] group consisting of:

(i) amino acid sequence, which does not have an adverse influence on the water solubility of the lipopeptide or lipoprotein;

(ii) GQTNT (SEQ ID NO:1);

(iii) SKKKK (SEQ ID NO:2);

(iv) GNNDESNISFKEK (SEQ ID NO:3);

(v) GQTDNNSSQSQQPGSGTTNT (SEQ ID NO:4);

[where, in amino acid sequences (ii), (iii), (iv) and (v), individual amino acids may be absent or replaced] or a fragment or variant of the amino acid sequences in (ii), (iii), (iv) and (v) wherein said fragment or variant has macrophage stimulating activity.

4. (Currently Amended) [Application according to one of the previous Claims] The method of claim 1[, where] wherein the C_{7-25}-alkyl, C_{7-25}-alkenyl, or C_{7-25}-alkinyl is a C_{15}-alkyl, C_{15}-alkenyl or C_{15}-alkinyl, respectively.

5. (Currently Amended) [Application according to one of the previous Claims] The method of claim 1[, where] wherein the double bond(s) in the C_{7-25}-alkenyl group has(have) the cis-configuration.

6. (Currently Amended) [Application of] A method of treating a wound in an animal or human comprising administering to an animal or human a physiologically compatible lipopeptide or lipoprotein which carries at the N-terminal a dihydroxypropyl cysteine group with two[, optionally long-chain], fatty acids bonded via ester bonds[, which wherein said fatty acids may can be the same or different, for the preparation of a pharmaceutical preparation for the treatment of animal and human wounds].

7. (Currently Amended) [Application of] The method of claim 1 wherein said lipopeptide or lipoprotein [obtainable] is obtained from a mycoplasma clone [for the treatment of wounds in animals or humans].

8. (Currently Amended) [Application according to] The method of Claim 7, [characterized by the fact that the] wherein said lipopeptide or lipoprotein [can be] is obtained from a *Mycoplasma fermantans* clone.

9. (Currently Amended) [Application according to one of the previous Claims] The method of claim 1 wherein said[, where] the lipopeptide or lipoprotein is water-soluble or amphoteric.

10. (Currently Amended) [Application according to one of the previous Claims of a] The method of claim 1 wherein said lipopeptide or lipoprotein selected from the group consists of:

(i) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-GQTNT (SEQ ID NO:5)

(ii) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-SKKKK (SEQ ID NO:6)

(iii) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-

GNNDESNISFKEK (SEQ ID NO:7)

(iv) S-[2,3-bispalmitoyloxy-(2S)-propyl]cysteinyl-

GNNDESNISFKEK (SEQ ID NO:8) and

(v) S-[2,3-bispalmitoyloxypropyl]cysteinyl-

GQTDNNSSQSQQPGSGTTNT (SEQ ID NO:9)

11. (Currently Amended) [Application according to one of the previous Claims, where the] The method of claim 1 wherein said lipopeptide or lipoprotein [can be] is in the form of a solution for epicutaneous application, an injection solution, a salve, a lotion, an aqueous suspension, a plaster impregnated or coated with [it] said lipopeptide or lipoprotein, encapsulated in liposomes, or coupled to biodegradable carrier polymers.

12. (Currently Amended) [Application according to one of the previous Claims] The method of claim 1 wherein said wound is a wound [with the wounds being wounds] after injury or surgical intervention, a chronically infected [wounds] wound, a burn [wounds] wound, a chronic [ulcers or], *Ulcus venosum*, or a [wounds] wound of a [patients] patient who [are] is corpulent or diabetic or are subjected to radiation or chemotherapy.

13. (New) The method of claim 1 wherein R^1 and R^2 and the same.

14. (New) The method of claim 1 wherein R^1 and R^2 are different.

15. (New) The method of claim where Z^1 and Z^2 are the same.

16. (New) The method of claim where Z^1 and Z^2 are different.

17. (New) The method of claim 6 wherein said fatty acids are long-chain fatty acids.

18. (New) The method of claim 6 wherein said fatty acids are the same.

19. (New) The method of claim 6 wherein said fatty acids are different.